OncoMatch/Clinical Trials/NCT05892718
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Is NCT05892718 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HCB101 for advanced solid tumor.
Treatment: HCB101 — The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic cancer therapy
advanced solid tumors refractory to standard therapy, or for which no standard treatment exists or non-Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of therapy
Cannot have received: CD47 or SIRPA pathway inhibitor
Have received any treatment targeting the CD47 or SIRPα pathway
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hematology-Oncology Associates of the Treasure Coast · Port Saint Lucie, Florida
- Carolina BioOncology · Huntersville, North Carolina
- Greenville Hospital System University Medical Center (ITOR) · Greenville, South Carolina
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify